Elite in Pulmonary Fibrosis

Helen Parfrey

Cambridge, ENG, GB 
Elite in Pulmonary Fibrosis
Cambridge, ENG, GB 
OverviewLocationsClinical Research

Overview

Helen Parfrey practices in Cambridge, United Kingdom. Ms. Parfrey is rated as an Elite expert by MediFind in the treatment of Pulmonary Fibrosis. Her top areas of expertise are Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Interstitial Lung Disease, Acute Interstitial Pneumonia, and Lung Transplant.

Her clinical research consists of co-authoring 44 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 31 articles and participated in 2 clinical trials in the study of Pulmonary Fibrosis.

Gender
Female

Locations

Cambridge, ENG, United Kingdom
Other Locations
Papworth Everard, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug, Other
Study Drug: ND-L02-s0201
Study Phase: Phase 2
View 1 Less Clinical Trial

44 Total Publications

Sex-specific genetic effects on susceptibility to idiopathic pulmonary fibrosis.
Sex-specific genetic effects on susceptibility to idiopathic pulmonary fibrosis.
Journal: ERJ open research
Published: February 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Parfrey's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile